Immunome Past Earnings Performance
Past criteria checks 0/6
Immunome's earnings have been declining at an average annual rate of -38.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been growing at an average rate of 102.6% per year.
Key information
-38.3%
Earnings growth rate
34.1%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 102.6% |
| Return on equity | -89.1% |
| Net Margin | -761.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Immunome: Why It Has Doubled Over The Last Month
Jan 18Will Immunome (NASDAQ:IMNM) Spend Its Cash Wisely?
Mar 17
Is Immunome (NASDAQ:IMNM) In A Good Position To Deliver On Growth Plans?
Nov 20Immunome GAAP EPS of -$0.74
Aug 05Here's Why We're Watching Immunome's (NASDAQ:IMNM) Cash Burn Situation
Aug 05Immunome gains 34% after preclinical data on COVID-19 antibody
Jun 30We Think Immunome (NASDAQ:IMNM) Can Afford To Drive Business Growth
Feb 21Companies Like Immunome (NASDAQ:IMNM) Are In A Position To Invest In Growth
Oct 02Immunome launches $27M private placement
Apr 26Do Institutions Own Immunome, Inc. (NASDAQ:IMNM) Shares?
Mar 12Read This Before Selling Immunome, Inc. (NASDAQ:IMNM) Shares
Jan 18Immunome EPS misses by $7.22
Nov 17Revenue & Expenses BreakdownBeta
How Immunome makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 14 | -107 | 20 | 0 |
| 30 Sep 23 | 10 | -22 | 15 | 23 |
| 30 Jun 23 | 7 | -27 | 14 | 23 |
| 31 Mar 23 | 2 | -30 | 13 | 23 |
| 31 Dec 22 | 0 | -38 | 14 | 0 |
| 30 Sep 22 | 0 | -38 | 14 | 4 |
| 30 Jun 22 | 0 | -36 | 13 | 9 |
| 31 Mar 22 | 0 | -32 | 13 | 12 |
| 31 Dec 21 | 0 | -25 | 11 | 14 |
| 30 Sep 21 | 0 | -21 | 10 | 12 |
| 30 Jun 21 | 0 | -22 | 8 | 9 |
| 31 Mar 21 | 0 | -19 | 6 | 7 |
| 31 Dec 20 | 0 | -18 | 5 | 7 |
| 30 Sep 20 | 0 | -17 | 3 | 8 |
| 30 Jun 20 | 0 | -11 | 2 | 9 |
| 31 Mar 20 | 0 | -11 | 2 | 9 |
| 31 Dec 19 | 0 | -10 | 2 | 9 |
Quality Earnings: IMNM is currently unprofitable.
Growing Profit Margin: IMNM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMNM is unprofitable, and losses have increased over the past 5 years at a rate of 38.3% per year.
Accelerating Growth: Unable to compare IMNM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMNM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: IMNM has a negative Return on Equity (-89.09%), as it is currently unprofitable.